<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: The oral <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> agent <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> improves insulin sensitivity and glycemic control and appears to lower atherogenic dense <z:chebi fb="15" ids="39026">LDL</z:chebi> in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000855'>Insulin resistance</z:hpo> may occur frequently in nondiabetic patients with <z:hpo ids='HP_0000822'>hypertension</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>This study is the first to report the effect of <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> on <z:chebi fb="15" ids="39026">LDL</z:chebi> subfractions in normolipidemic, nondiabetic patients with arterial <z:hpo ids='HP_0000822'>hypertension</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>RESEARCH DESIGN AND METHODS: We performed a monocentric, double-blind, randomized, parallel-group comparison of 45 mg <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> (n = 26) and a placebo (n = 28), each given once daily for 16 weeks </plain></SENT>
<SENT sid="4" pm="."><plain>Fifty-four moderately hypertensive patients (<z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi>, 2.8 +/- 0.8 mmol/l; <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi>, 1.1 +/- 0.3 mmol/l; <z:chebi fb="4" ids="17855">triglycerides</z:chebi>, 1.4 mmol/l (median; range 0.5-7.1) were studied at baseline and on treatment </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: At baseline, dense <z:chebi fb="15" ids="39026">LDLs</z:chebi> were elevated (<z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> [apo]B in <z:chebi fb="15" ids="39026">LDL</z:chebi>-5 plus <z:chebi fb="15" ids="39026">LDL</z:chebi>-6 &gt;250 mg/l) in 63% of <z:hpo ids='HP_0000001'>all</z:hpo> patients </plain></SENT>
<SENT sid="6" pm="."><plain>Sixteen weeks of treatment with <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> did not significantly change <z:chebi fb="4" ids="17855">triglycerides</z:chebi>, total, <z:chebi fb="15" ids="39026">LDL</z:chebi>, and <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>However, <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> reduced dense <z:chebi fb="15" ids="39026">LDLs</z:chebi> by 22% (P = 0.024) </plain></SENT>
<SENT sid="8" pm="."><plain>The mean diameter of <z:chebi fb="15" ids="39026">LDL</z:chebi> particles increased from 19.83 +/- 0.30 to 20.13 +/- 0.33 nm (P &lt; 0.001 vs. placebo), whereas the mean <z:chebi fb="15" ids="39026">LDL</z:chebi> density decreased from 1.0384 +/- 0.0024 to 1.0371 +/- 0.0024 kg/l (P = 0.005 vs. placebo) </plain></SENT>
<SENT sid="9" pm="."><plain>The effect of <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> on <z:chebi fb="15" ids="39026">LDL</z:chebi> size and density was independent of fasting <z:chebi fb="4" ids="17855">triglycerides</z:chebi> and <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> at baseline and of changes in fasting <z:chebi fb="4" ids="17855">triglycerides</z:chebi> and <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: The prevalence of atherogenic dense <z:chebi fb="15" ids="39026">LDL</z:chebi> in nondiabetic, hypertensive patients is similar to patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="11" pm="."><plain><z:chebi fb="0" ids="8228">Pioglitazone</z:chebi> significantly reduces dense <z:chebi fb="15" ids="39026">LDL</z:chebi> independent from fasting <z:chebi fb="4" ids="17855">triglycerides</z:chebi> and <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> </plain></SENT>
<SENT sid="12" pm="."><plain>The antiatherogenic potential of <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> may thus be greater than that expected from its effects on <z:chebi fb="4" ids="17855">triglycerides</z:chebi>, <z:chebi fb="15" ids="39026">LDL</z:chebi>, and <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> alone </plain></SENT>
</text></document>